Anika Therapeutics (NASDAQ:ANIK) Price Target Raised to $17.00

Anika Therapeutics (NASDAQ:ANIK) had its target price boosted by Barrington Research from $16.00 to $17.00 in a report issued on Friday morning,Benzinga reports. They currently have an outperform rating on the biotechnology company’s stock.

A number of other brokerages also recently weighed in on ANIK. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Anika Therapeutics in a research note on Monday, December 29th. Wall Street Zen raised shares of Anika Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Anika Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $19.00.

Anika Therapeutics Stock Performance

Shares of ANIK stock opened at $14.36 on Friday. The company has a market capitalization of $207.07 million, a PE ratio of -18.89 and a beta of 0.33. Anika Therapeutics has a 52-week low of $7.87 and a 52-week high of $17.74. The business’s fifty day moving average is $9.96 and its 200 day moving average is $9.57.

Anika Therapeutics (NASDAQ:ANIK) last announced its earnings results on Thursday, February 26th. The biotechnology company reported $0.31 earnings per share for the quarter, topping analysts’ consensus estimates of $0.02 by $0.29. Anika Therapeutics had a negative return on equity of 6.26% and a negative net margin of 9.64%.The business had revenue of $30.62 million for the quarter, compared to analyst estimates of $28.88 million. On average, sell-side analysts forecast that Anika Therapeutics will post -0.84 EPS for the current fiscal year.

Hedge Funds Weigh In On Anika Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in ANIK. Invesco Ltd. raised its position in Anika Therapeutics by 7.9% in the 4th quarter. Invesco Ltd. now owns 25,272 shares of the biotechnology company’s stock worth $243,000 after purchasing an additional 1,843 shares during the period. Corient Private Wealth LLC grew its stake in shares of Anika Therapeutics by 4.3% during the fourth quarter. Corient Private Wealth LLC now owns 32,224 shares of the biotechnology company’s stock valued at $310,000 after buying an additional 1,324 shares during the last quarter. Mercer Global Advisors Inc. ADV purchased a new position in shares of Anika Therapeutics in the fourth quarter worth about $122,000. NewEdge Advisors LLC purchased a new position in shares of Anika Therapeutics in the fourth quarter worth about $139,000. Finally, XTX Topco Ltd lifted its stake in shares of Anika Therapeutics by 74.3% in the 4th quarter. XTX Topco Ltd now owns 22,252 shares of the biotechnology company’s stock valued at $214,000 after acquiring an additional 9,482 shares during the last quarter. Institutional investors own 91.53% of the company’s stock.

Anika Therapeutics News Summary

Here are the key news stories impacting Anika Therapeutics this week:

• Positive Sentiment: Q4 results beat expectations — non‑GAAP EPS $0.31 vs. $0.02 consensus and revenue $30.6M vs. $28.9M consensus; the beat is the primary near‑term catalyst. Zacks: ANIK Q4 Earnings Beat
• Positive Sentiment: Barrington Research raised its price target to $17 and moved to an “Outperform,” signaling analyst confidence and providing upside to the stock. Benzinga: Barrington Research Upgrade
• Positive Sentiment: Company reiterated 2026 revenue guidance (roughly $114.0M–$122.5M reported) and set an adjusted EBITDA target while highlighting commercial‑channel expansion (commercial channel +22% in Q4, +15% full year), supporting a constructive near‑term growth outlook. GlobeNewswire: Q4 & Full‑Year 2025 Results
• Positive Sentiment: Management emphasized operational streamlining and commercial expansion, and generated positive operating cash flow ($11.2M) and free cash flow ($4.4M) for 2025 — items investors often view favorably for mid‑cycle biotech/medical device firms. Seeking Alpha: 2026 Outlook & Commercial Expansion
• Neutral Sentiment: Earnings call transcript and slide materials are available for details on product cadence, margin drivers and timing of regulatory milestones — useful for investors but not an immediate price mover by itself. SA: Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Reported short‑interest data in recent feeds appears to be erroneous (shows zero shares / NaN changes); no clear short‑squeeze signal from the published data. MarketBeat: ANIK Data
• Negative Sentiment: Regulatory risk: the FDA sent a response on the Hyalofast® PMA in January and Anika is preparing responses — this implies additional work/possible delays before approval and commercialization. GlobeNewswire: Regulatory Update
• Negative Sentiment: Company still reports negative net margin and negative return on equity; some analysts project a negative full‑year EPS — these fundamentals limit valuation support until profitability trends improve. MarketBeat: Earnings Summary

Anika Therapeutics Company Profile

Anika Therapeutics, Inc is a life sciences company specializing in the development and commercialization of hyaluronic acid–based therapeutic products. The company focuses on orthobiologics and medical devices designed to support joint health, tissue repair and surgical applications. Anika’s proprietary hyaluronan technology serves as the foundation for products aimed at alleviating pain associated with osteoarthritis and enhancing healing in musculoskeletal and ophthalmic surgeries.

The company’s core product portfolio includes injectable viscosupplements such as Monovisc® and Orthovisc®, which are indicated for the relief of knee osteoarthritis pain, as well as Euflexxa®, approved for osteoarthritis of the knee in various international markets.